Background and aims: Cannabis and tobacco use is common in Great Britain. Use of both substances has been associated with mental health problems, but prevalence of their co-use and implications on mental health are unknown. We aimed to 1) estimate prevalence of cannabis use, frequency of use and routes of administration (ROA) among smokers and non-smokers; 2) to investigate mental health problems amongst non-users, tobacco-only, cannabis-only and co-users of both substances. Design: National online survey fielded in February–March 2020. Setting: Great Britain Participants: Adults in Great Britain aged ≥ 18 year (n = 12,809) Measurements: Tobacco use status (smoker [daily or non-daily] or non-smoker [never or ex-smoker]), cannabis use frequency (never to daily), detailed ROAs of cannabis, mental health disorders (depression, anxiety, and any). Weighted prevalence estimates were computed and correlates assessed using chi-squared tests and logistic regression. Findings: In Great Britain in 2020, 7.1% of British adults had used cannabis in the past year. Tobacco smokers has greater odds of using cannabis in the past year (21.9%) and using cannabis daily (8.7%) than non-smokers (past-year: 4.7%; aOR=10.07, [95% CI: 8.4 -12.0]; daily: 0.7%; aOR=24.6, [95% CI: 17.96-35.55]). Co-administration with tobacco was common (46.2% of non-smokers, 80.8% of smokers). Co-users reported the highest prevalence of any mental health problem (54.2%) in comparison to cannabis-only (45.8%), tobacco-only (33.2%) and non-users (22.7%; all p≤0.05). Conclusion: In a representative sample of Great Britain in 2020, tobacco smokers and non-smokers show significant exposure to combusted smoke and tobacco smoke. Self-identified non-smokers who regularly consume combusted cannabis, and smoked cannabis with tobacco warrant further attention. Co-use was associated with greater daily cannabis use, co-administration and mental health problems. Cannabis users should be considered a vulnerable population where rates of tobacco smoking are much higher than in the general population.
No takes yet. Share an insight, caveat, or question.
Hindocha et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: